Other equities research analysts have also issued research reports about the stock. Zacks Investment Research raised shares of Medpace from a hold rating to a buy rating and set a $71.00 target price for the company in a research note on Wednesday, July 10th. Credit Suisse Group lifted their target price on shares of Medpace from $65.00 to $77.00 and gave the company an outperform rating in a research note on Tuesday, July 30th. ValuEngine raised shares of Medpace from a hold rating to a buy rating in a research note on Tuesday, July 2nd. Robert W. Baird lifted their target price on shares of Medpace from $57.00 to $62.00 and gave the company a neutral rating in a research note on Tuesday, April 30th. Finally, TheStreet raised shares of Medpace from a c rating to a b- rating in a research note on Thursday, June 6th. One analyst has rated the stock with a hold rating, five have assigned a buy rating and one has given a strong buy rating to the company. Medpace has an average rating of Buy and an average target price of $73.75.
Medpace stock traded down $1.96 during midday trading on Friday, reaching $76.48. The stock had a trading volume of 683,089 shares, compared to its average volume of 493,074. The firm has a fifty day moving average of $63.87. Medpace has a twelve month low of $45.88 and a twelve month high of $80.65. The company has a debt-to-equity ratio of 0.07, a quick ratio of 0.69 and a current ratio of 0.66. The firm has a market cap of $2.82 billion, a price-to-earnings ratio of 29.53, a price-to-earnings-growth ratio of 2.16 and a beta of 1.57.
Several institutional investors have recently added to or reduced their stakes in the company. Swiss National Bank raised its holdings in shares of Medpace by 9.0% during the 2nd quarter. Swiss National Bank now owns 53,100 shares of the company’s stock valued at $3,474,000 after purchasing an additional 4,400 shares in the last quarter. Envestnet Asset Management Inc. raised its holdings in shares of Medpace by 212.8% during the 2nd quarter. Envestnet Asset Management Inc. now owns 24,501 shares of the company’s stock valued at $1,603,000 after purchasing an additional 16,667 shares in the last quarter. Sigma Planning Corp bought a new position in shares of Medpace during the 2nd quarter valued at $305,000. DekaBank Deutsche Girozentrale raised its holdings in shares of Medpace by 62.5% during the 2nd quarter. DekaBank Deutsche Girozentrale now owns 26,000 shares of the company’s stock valued at $1,668,000 after purchasing an additional 10,000 shares in the last quarter. Finally, Advisory Services Network LLC bought a new position in shares of Medpace during the 2nd quarter valued at $828,000. Institutional investors and hedge funds own 77.30% of the company’s stock.
Medpace Company Profile
Medpace Holdings, Inc, a clinical contract research organization, provides scientifically-driven outsourced clinical development services to the biotechnology, pharmaceutical, and medical device industries worldwide. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in a range of therapeutic areas.
Featured Story: When can a hold rating present a buying opportunity?
Receive News & Ratings for Medpace Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medpace and related companies with MarketBeat.com's FREE daily email newsletter.